Matches in Wikidata for { <http://www.wikidata.org/entity/Q90358401> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- Q90358401 description "article scientifique publié en 2018" @default.
- Q90358401 description "artículu científicu espublizáu en xunu de 2018" @default.
- Q90358401 description "scientific article published on 01 June 2018" @default.
- Q90358401 description "wetenschappelijk artikel" @default.
- Q90358401 description "наукова стаття, опублікована в червні 2018" @default.
- Q90358401 name "Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysi" @default.
- Q90358401 name "Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysi" @default.
- Q90358401 type Item @default.
- Q90358401 label "Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysi" @default.
- Q90358401 label "Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysi" @default.
- Q90358401 prefLabel "Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysi" @default.
- Q90358401 prefLabel "Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysi" @default.
- Q90358401 P1433 Q90358401-D6436FD6-570E-4413-AA41-B1A39E4D453B @default.
- Q90358401 P1476 Q90358401-BBDC4B91-1DEF-4FD7-89B1-2FEB05FE7A71 @default.
- Q90358401 P2093 Q90358401-0031ED58-8FC1-45D9-B13A-F4D21D316026 @default.
- Q90358401 P2093 Q90358401-08F1C908-76C1-45CE-9AE7-32651759D399 @default.
- Q90358401 P2093 Q90358401-0CE72B2A-16DB-48B0-B7F6-670BC98C96C6 @default.
- Q90358401 P2093 Q90358401-27138C92-84BC-43BA-A5AE-24BADD657063 @default.
- Q90358401 P2093 Q90358401-398EF71C-0403-4B73-8F9B-E2BA9692F837 @default.
- Q90358401 P2093 Q90358401-3A67F100-386E-4A82-941A-2231DB4108C9 @default.
- Q90358401 P2093 Q90358401-3C126A94-19FB-4F61-95AE-A399C52B704C @default.
- Q90358401 P2093 Q90358401-3E497F9D-CE01-4309-A9B2-C4F224A41E31 @default.
- Q90358401 P2093 Q90358401-4BAB8B3B-D6DE-43AA-80FE-0F0E951AD02F @default.
- Q90358401 P2093 Q90358401-5A124BEF-C103-423C-B673-61A88DAA8921 @default.
- Q90358401 P2093 Q90358401-5D781B55-9644-41AB-A145-8C66D9678248 @default.
- Q90358401 P2093 Q90358401-8CFBA3F2-1967-4935-90A0-EB3B7842CE32 @default.
- Q90358401 P2093 Q90358401-AC2D199B-3B84-4747-9010-619D838761BC @default.
- Q90358401 P2093 Q90358401-B1182F6C-B701-4326-804A-C17DBBD19E64 @default.
- Q90358401 P2093 Q90358401-BE9EC3B1-C18F-4BBA-9E0F-476CE028176D @default.
- Q90358401 P2093 Q90358401-DD1C608C-0B0E-42C0-BB12-67136DD442D2 @default.
- Q90358401 P2093 Q90358401-DD711581-62FC-4158-B36C-A543AA4ADA34 @default.
- Q90358401 P2093 Q90358401-F755A8ED-A264-475C-9228-99A540460780 @default.
- Q90358401 P304 Q90358401-15B71790-0004-4288-BE90-FBCAB9495199 @default.
- Q90358401 P31 Q90358401-59E1C195-2E53-477F-8E63-7F12FEDF5082 @default.
- Q90358401 P356 Q90358401-363DD382-0BBF-4187-81C4-9CE754C704AE @default.
- Q90358401 P478 Q90358401-1A53E2C1-FE2B-48DC-9F4C-1FA502A02364 @default.
- Q90358401 P50 Q90358401-A897448C-AF01-4EA3-91E1-7004933E2DBB @default.
- Q90358401 P577 Q90358401-9BBAEAEE-2B91-402B-AACA-D1B3466D35D1 @default.
- Q90358401 P921 Q90358401-06D7A792-AB83-4C04-BAEF-B99BAF646804 @default.
- Q90358401 P921 Q90358401-89B0E9D1-6678-44BD-9939-466001F0076F @default.
- Q90358401 P921 Q90358401-B0BEE9DB-9395-4779-A6DF-5379CEC8BC89 @default.
- Q90358401 P921 Q90358401-FB2884E4-7DF7-403C-98A4-3358E0187BD1 @default.
- Q90358401 P356 MDY149.021 @default.
- Q90358401 P1433 Q326122 @default.
- Q90358401 P1476 "Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis" @default.
- Q90358401 P2093 "A Kanehisa" @default.
- Q90358401 P2093 "A Ten Tije" @default.
- Q90358401 P2093 "A Van de Wouw" @default.
- Q90358401 P2093 "C Borg" @default.
- Q90358401 P2093 "C Punt" @default.
- Q90358401 P2093 "D Stroyakovskiy" @default.
- Q90358401 P2093 "E Van Cutsem" @default.
- Q90358401 P2093 "G Argiles" @default.
- Q90358401 P2093 "G Creemers" @default.
- Q90358401 P2093 "H Wasan" @default.
- Q90358401 P2093 "K Lesniewski-Kmak" @default.
- Q90358401 P2093 "M Fedyanin" @default.
- Q90358401 P2093 "M Saunders" @default.
- Q90358401 P2093 "N Amellal" @default.
- Q90358401 P2093 "N Lopez Busto" @default.
- Q90358401 P2093 "R Fougeray" @default.
- Q90358401 P2093 "R Glynne-Jones" @default.
- Q90358401 P2093 "V Moiseenko" @default.
- Q90358401 P304 "v108" @default.
- Q90358401 P31 Q13442814 @default.
- Q90358401 P356 "10.1093/ANNONC/MDY149.021" @default.
- Q90358401 P478 "29 Suppl 5" @default.
- Q90358401 P50 Q56839877 @default.
- Q90358401 P577 "2018-06-01T00:00:00Z" @default.
- Q90358401 P921 Q108566365 @default.
- Q90358401 P921 Q188874 @default.
- Q90358401 P921 Q413299 @default.
- Q90358401 P921 Q420207 @default.